Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
73 studies found for:    cabozantinib
Show Display Options
Rank Status Study
1 Active, not recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
2 Recruiting A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
3 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
4 Active, not recruiting A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma of the Extrahepatic Bile Duct
Intervention: Drug: Cabozantinib
5 Recruiting Cabozantinib for Malignant Pheochromocytoma
Condition: Neuroendocrine Tumors
Interventions: Drug: Cabozantinib;   Behavioral: Questionnaire
6 Active, not recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
7 Completed Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Conditions: Solid Tumors;   Cancer;   NSCLC
Interventions: Drug: cabozantinib capsules;   Drug: cabozantinib tablets
8 Terminated
Has Results
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
9 Active, not recruiting Cabozantinib in Advanced Solid Malignancies
Conditions: Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
10 Completed
Has Results
Cabozantinib for Metastatic Triple Negative BrCa
Condition: Breast Cancer
Intervention: Drug: Cabozantinib
11 Active, not recruiting XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Condition: Multiple Myeloma
Intervention: Drug: Cabozantinib
12 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Placebo tablets
13 Active, not recruiting Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Childhood Thyroid Gland Medullary Carcinoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Melanoma;   Recurrent Thyroid Gland Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
14 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
15 Completed Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
Conditions: Healthy;   Hepatic Impairment
Intervention: Drug: cabozantinib
16 Active, not recruiting A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: CABOZANTINIB;   Drug: gemcitabine
17 Recruiting Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Cabozantinib
18 Completed Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: prednisone
19 Active, not recruiting Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Cabozantinib;   Drug: Androgen Ablation Therapy
20 Active, not recruiting A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Everolimus (Afinitor) tablets

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.